Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jun 7, 2012 (14 years ago)

Erythromycin Topical Solution USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Chemical Contamination: This product is being recalled because trace amounts of a plasticizer (Di-Octyl Phthalate) may be present in the product.

Cause type: Chemical / undeclared

A chemical that should not be there - benzene, methanol, lead - or an undeclared prescription drug hidden in a supplement. The label gives no warning: you may be taking a toxic solvent, a heavy metal, or a drug such as sildenafil that interacts with your other medicines. All chemical / undeclared recalls.

What was recalled

Erythromycin Topical Solution USP, 2%, 60 mL bottle with applicator, Rx only. E. FOUGERA & CO., A division of Fougera Pharmaceuticals, Inc., Melville, New York 11747, NDC 0168-0215-60, UPC 3 0168-0215-60 0.

Affected NDC 0168-0215-60

Compare with the code on your package — it is the most precise check available.

Drug: Erythromycin

Recalling firm
Fougera Pharmaceuticals, Inc.
NDC code
0168-0215-60
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1426-2012 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Erythromycin recalls

See all
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1048-3 D-0545-2026
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1047-3 D-0544-2026
Class II · Moderate risk

Erythromycin Topical Gel USP

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Ongoing Stability / shelf life McKesson Corporation dba McKesson Drug Company NDC 63739-053-68 D-0851-2022

Other recalls by Fougera Pharmaceuticals, Inc.

All 2012 recalls
Class II · Moderate risk

Desonide Ointment

Labeling: Label Mixup; Unit boxes labeled as Desonide Ointment 0.05% may contain tubes of Desonide Ointment labeled as Ketoconazole Cream

Terminated Labeling / mix-up Fougera Pharmaceuticals Inc. NDC 0168-0309-60 D-0612-2017
Class II · Moderate risk

Fluocinonide Gel USP

Failed Stability Specifications: The lots of Fluocinonide Gel USP, 0.05% recalled, may not meet the requirements for residual solvents as outlined in USP <467>.

Terminated Stability / shelf life Fougera Pharmaceuticals Inc. NDC 0168-0135-15 D-0245-2015
Class III · Low risk

Triamcinolone Acetonide Lotion USP

Failed PH Specifications: It has been determined that the pH of the lots recalled, may not meet specification at expiry.

Terminated Failed specification Fougera Pharmaceuticals Inc. NDC 0168-0336-60 D-1441-2014
Class III · Low risk

Triamcinolone Acetonide Lotion USP

Failed PH Specifications: It has been determined that the pH of the lots recalled, may not meet specification at expiry.

Terminated Failed specification Fougera Pharmaceuticals Inc. NDC 0168-0337-60 D-1440-2014